ArticlePharmacology research & perspectives2020
The metabolic effects of mirabegron are mediated primarily by β
Article in Pharmacology research & perspectives, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- Thermogenic Targets for Obesity Management in the Era of Incretin-Based Therapies.Pharmaceuticals (Basel, Switzerland) · 2025Review
- D-Glucose and its derivatives labeled with radioactive carbon and hydrogen: key tools for investigating biological processes and molecular mechanisms.EJNMMI radiopharmacy and chemistry · 2025Review
- Emerging debates and resolutions in brown adipose tissue research.Cell metabolism · 2025Review
- Keys to the switch of fat burning: stimuli that trigger the uncoupling protein 1 (UCP1) activation in adipose tissue.Lipids in health and disease · 2024Review
- The Different Shades of Thermogenic Adipose Tissue.Current obesity reports · 2024Review
- Adrenoceptors: Receptors, Ligands and Their Clinical Uses, Molecular Pharmacology and Assays.Handbook of experimental pharmacology · 2024Review
- Mirabegron displays anticancer effects by globally browning adipose tissues.Nature communications · 2023Article
- Mirabegron, a Selective β3-Adrenergic Receptor Agonist, as a Potential Anti-Obesity Drug.Journal of clinical medicine · 2023Review
- Pharmacological Support for the Treatment of Obesity-Present and Future.Healthcare (Basel, Switzerland) · 2023Review
- β3-Adrenergic receptors regulate human brown/beige adipocyte lipolysis and thermogenesis.JCI insight · 2021Article
- Targeting Adrenergic Receptors in Metabolic Therapies for Heart Failure.International journal of molecular sciences · 2021Review
- Central vs. Peripheral Action of Thyroid Hormone in Adaptive Thermogenesis: A Burning Topic.Cells · 2021Review
- The metabolic effects of mirabegron are mediated primarily by βPharmacology research & perspectives · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The β
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.